Newsfilter article unlocker
Enter Newsfilter article ID in the field below. Example: https://newsfilter.io/articles/39be1bef03e66cdc886c08a2a6319c47
Retrieved article
GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab
Feb 25 (Reuters) - GSK (GSK.L), opens new tab on Wednesday agreed to pay $950 million in cash for Canadian biopharmaceutical company 35Pharma Inc, which is developing a medicine for pulmonary hypertension.
The deal marks GSK's second major acquisition under new CEO Luke Miels, after it agreed to buy RAPT Therapeutics (RAPT.O), opens new tab for $2.2 billion in January.
GSK will acquire 35Pharma's in-development drug to treat pulmonary hypertension, a life-shortening disease marked by high blood pressure in the lungs, helping the company expand its respiratory portfolio.
The British drugmaker earlier this week agreed to a $1 billion deal to acquire global rights to develop Frontier Biotechnologies' (688221.SS), opens new tab two small interfering RNA therapies targeting kidney diseases.
Reporting by Prerna Bedi in Bengaluru; Editing by Mrigank Dhaniwala
Our Standards: The Thomson Reuters Trust Principles., opens new tab
